CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.09BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.0100xvs all stocks
52-Week Change
135.24%vs all stocks
Market Capitalization
1.09BUSDvs all stocks (USD)
Enterprise Value
737.69MUSDvs all stocks (USD)
Forward P/E
-7.00xvs Biotechnology peers
Price to Book (MRQ)
2.97xvs Biotechnology peers
Enterprise to EBITDA
-3.07xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-30.57%vs Biotechnology peers
Return on Equity (TTM)
-48.16%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-240.04MUSDvs all stocks (USD)
Net Income (TTM)
-221.04MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-178.64MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-102.82MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-241.65MUSDvs all stocks (USD)
Pre-tax Income
-219.88MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-219.88MUSDFY2025 · Dec 31, 2025EBIT
-241.65MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-241.34MUSDFY2025 · Dec 31, 2025Research & Development
187.40MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
54.25MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
22.21MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-219.88MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-184.37MUSDFY2025 · Dec 31, 2025Free Cash Flow
-184.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
88.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-219.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
311.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.04MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-839.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-49.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-236.53MUSDFY2025 · Dec 31, 2025Sale of Investments
416.57MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
179.99MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
61.45MSharesUpdated Jul 18, 2026Float Shares
44.16MSharesUpdated Jul 18, 2026Shares Short
10.60MSharesUpdated Jul 18, 2026Short Ratio
7.24daysvs all stocks
Short % of Shares Outstanding
24.47%vs all stocks
% Held by Insiders
0.45%vs all stocks
% Held by Institutions
107.69%vs all stocks
Total Cash (MRQ)
351.88MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.73USDUpdated Jul 18, 2026Total Debt (MRQ)
2.38MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0065xvs Biotechnology peers
Current Ratio (MRQ)
10.28xvs Biotechnology peers
Book Value per Share (MRQ)
5.96USDUpdated Jul 18, 2026Total Assets
448.37MUSDvs all stocks (USD)
Total Current Assets
386.76MUSDFY2025 · Dec 31, 2025Total Liabilities
39.64MUSDFY2025 · Dec 31, 2025Total Non-current Assets
61.62MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.90MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
88.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
289.56MUSDFY2025 · Dec 31, 2025Accounts Payable
841.00KUSDFY2025 · Dec 31, 2025Short-term Debt
780.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
996.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.90MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-588.12MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
408.73MUSDvs all stocks (USD)
52-Week Low
5.68USDUpdated Jul 18, 202652-Week High
19.43USDUpdated Jul 18, 202652-Week Change
135.24%vs all stocks
Beta
-0.0100xvs all stocks
50-Day MA
15.87USDUpdated Jul 18, 2026200-Day MA
12.51USDUpdated Jul 18, 2026Avg 10-Day Volume
646.95KSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.19MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-3.37USDUpdated Jul 18, 2026Other Income / Expense
-443.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.67
Altman Z-Score 13.77: safe zoneNotable
Altman Z-Score: 13.77
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Procept BioRobotics Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Kanion Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lifetech Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dezhan Health Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Changchun BCHT Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule